Related Experiment Video
Updated: Aug 14, 2026
04:59
Rotating the Intraocular Lens to Prevent Posterior Capsular Opacification in Cataract Surgeries
Published on: July 7, 2023
Prospective, randomized trial of Microvisc and Healon in routine phacoemulsification
1York Finch Eye Associates, Toronto, Ontario, Canada.
Journal of Cataract and Refractive Surgery
|June 1, 1997
Summary
Microvisc and Healon, both sodium hyaluronate viscoelastic agents, demonstrated comparable safety and efficacy in routine phacoemulsification. This clinical trial found no significant differences in outcomes between the two surgical aids.
Area of Science:
- Ophthalmology
- Surgical Innovation
- Biomaterials Science
Background:
- Phacoemulsification requires effective viscoelastic devices for intraocular lens insertion.
- Sodium hyaluronate-based viscoelastic agents are standard in cataract surgery.
- Evaluating new agents like Microvisc against established ones like Healon is crucial for surgical practice.
Purpose of the Study:
- To compare the safety and efficacy of Microvisc versus Healon in routine phacoemulsification.
- To assess visual outcomes, corneal health, and intraocular pressure following surgery with either viscoelastic agent.
Main Methods:
- A prospective, randomized clinical trial involving 100 patients undergoing phacoemulsification.
- Unmasked comparison of Microvisc and Healon in 100 eyes.
- Postoperative assessments included visual acuity, corneal thickness, and intraocular pressure at multiple time points.
Main Results:
- No statistically significant differences were observed between Microvisc and Healon groups across all follow-up assessments.
- Key parameters such as visual acuity, corneal thickness, and intraocular pressure remained comparable.
Conclusions:
- Both Microvisc and Healon are safe and effective viscoelastic agents for routine phacoemulsification.
- The study supports the use of Microvisc as a viable alternative to Healon, offering similar clinical outcomes.
